NetScientific plc ("NetScientific", the “Group” or the "Company") PDS Phase 2 Clinical Trial Update PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination London, UK – 21 October 2021 – NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has announced the temporary…
NetScientific plc ("NetScientific", the “Group” or the "Company") PDS Phase 2 Clinical Trial Update PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer London, UK – 05 October 2021 – NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that…
NetScientific plc ("NetScientific", the “Group” or the "Company") Investor Presentations London, UK – 04 October 2021 – NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, today outlines its investor communications timetable for the remainder of the year. Management will be presenting at a range of virtual retail focussed investor events, to discuss the Company’s recent results…
NetScientific plc ("NetScientific" or the "Company") Grant of Options to Directors London, UK – 29 September 2021 – NetScientific plc (AIM:NSCI), the international life sciences and sustainability, technology investment and commercialisation group, announces that on 28 September 2021 it granted a further 183,191 options over ordinary shares of 5p each (the "Ordinary Shares") to each of its Chief Executive Officer, Dr Ilian Iliev, and its Executive…
NetScientific plc (“NetScientific” or the “Company” or the “Group”) Interim Results for the six months ended 30 June 2021 London, UK - 29 September 2021: NetScientific Plc (AIM: NSCI), the international life sciences and sustainability, technology investment and commercialisation group, today announces its interim results for the six months ended 30 June 2021. 2021 reinforced the excellent progress made to date, which…
NetScientific plc ("NetScientific", the “Group” or the "Company") Notice of Results and Analyst Briefing London, UK – 29 September 2021 – NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, is expected to announce results for the half year ended 30 June 2021 on Wednesday 29 September 2021. Analyst Briefing: 09.30, Wednesday 29 September Management will be hosting…
NetScientific plc ("NetScientific", the “Group” or the "Company") Investment in Martlet Capital Limited London, UK – 16 September 2021 – NetScientific plc (AIM: NSCI), an active holding company in life sciences and sustainability technology investment, is pleased to announce an initial £1m investment in Martlet Capital Limited (“Martlet Capital”), which intends to acquire a portfolio of minority interests in the Cambridge high-tech cluster. NetScientific’s…
Francois Martelet, chief executive of NetScientific PLC (LON:NSCI) caught up with Proactive’s Andrew Scott to update on developments within the IP commercialisation specialist’s portfolio. https://youtu.be/_5_-vQTbvp0 Francois Martelet, chief executive of NetScientific PLC (LON:NSCI), caught up with Proactive's Andrew Scott to update on developments within the IP commercialisation specialist's portfolio. ''All of our companies are game-changing and unique in their sectors'', Martelet says. Most recently…
London, UK – 05 January 2018 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, today announces that its management team will attend the following key investor and partnering conferences in the first half of 2018: IDATE DigiWorld – London Members Yearly Meeting January 18th 2018 London, UK Francois Martelet, CEO, to attend BAB TAG Networking Event January 24th 2018 London, UK…
London, UK – 08 December 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group announces that Francois Martelet, Chief Executive Officer, will be presenting at the Shares Investor Evening in London at the Novotel Tower Bridge, London EC3N 2NR on Thursday 14 December at 19:30 GMT # # # For more information, please contact: NetScientific François R. Martelet, M.D., CEO…
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.